

Vitamin D Deficiency and Nutritional Rickets: Supplementation and Treatment in Infants and Children

Background

Vitamin D deficiency is a risk for

- Rapidly growing children (infants, young children and adolescents) in the UK, particularly in ethnic minority groups
- Children with chronic diseases such as cystic fibrosis, coeliac disease, liver disease, renal disease, cancer
- Children receiving certain drugs, e.g. anti-convulsants

In 2012, the UK Chief Medical Officers⁽¹⁾ issued advice on supplements for at risk children between 1 month and 5 years of age, and breastfeeding babies likely to be born vitamin D deficient (due to lack of maternal supplementation in pregnancy).

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213703/dh_132508.pdf

Uptake of supplementation programmes has historically been low, and in recent years rickets is being more commonly recognised in infants and children.⁽²⁾

Current UK government recommendations on Vitamin D supplementation to maintain bone and muscle health:

- Young people and children aged 5 years and over: consider taking a daily supplement containing 400units of vitamin D between October and March when there is limited sun exposure. All year round supplements could be considered for those who have very little or limited sun exposure or who have dark skin (because they may not be able to make enough vitamin D from sunlight).
- Infants and children aged 1-4 years: give a daily supplement containing 400units vitamin D
- **Babies from birth 1 year:** give a daily supplement containing 300-400units of vitamin D to babies who are breastfed or if they are taking less than 500ml of infant formula each day.

Table 1

Vitamin D supplementation (for children up to 5 years of age and those with insufficiency)*

The products listed in the table below do not need to be provided on prescription; they can be obtained through the child health clinics for patients up to 5 years of age. Alternatively supplements can be brought over the counter in pharmacies, supermarkets and health food outlets. Appropriate doses for supplementation are described in Table 2.

Population	Risk	Action
Group	Factors	
Infants < 6 months	Risk factors for low	Healthy Start [®] vitamin supplement, or standard dose of Dalivit [®] or Abidec [®]
and breast led	level, e.g. Asian and	
	African ethnicity	
Infants > 6 months	Breast fed or taking less than 500 ml infant formula	Healthy Start vitamin supplement, or standard dose of Dalivit [®] or Abidec [®]



All children		Healthy Start [®] vitamin supplement, or standard dose of Dalivit [®] or Abidec [®]
1-5 years		Safe sun exposure
		Dietary vitamin D and calcium advice
Insufficient vitamin		Follow vitamin D specific supplementation guidelines above until 5 years of age
D levels		and possibly throughout childhood
(see Table 3)		Safe sun exposure
		Dietary vitamin D and calcium advice
Chronic disease	e.g. cerebral palsy,	Follow disease specific prescribing guidelines or guidance in Table 3 of these
	neuromuscular	guidelines
	disorders, taking	Safe sun exposure
	anti-convulsant	Dietary vitamin D and calcium advice
	therapy, cystic	
	fibrosis,	
	malabsorption	

*Multivitamin supplements containing vitamin A should not be used in patients with chronic renal failure. These children should receive vitamin D alone as a supplement.

Table 2: Standard prevention doses⁴

Category	Dose and Frequency		
Newborn up to 1 month	300 – 400 units daily		
1 month – 18 years	400 units – 600 units daily Higher doses up to 1000units daily may be used		

NB. A dose of 10 micrograms of Vitamin D = 400 units

Assessment of vitamin D status

Supplementation can be initiated without testing and therefore biochemical testing for vitamin D deficiency is unnecessary for the majority of children in the primary care setting, unless they are symptomatic.

Follow agreed disease specific monitoring guidelines for those with underlying chronic conditions such as CF, cancer, neuromuscular disease, where these are available.

Total 25 (OH) Vitamin D (nmol/L)	Vitamin D status	Clinical status	Management
≤25	Deficiency	ency Infants: Rickets, bone pain, delayed walking Children: Chronic pain and weakness, tiredness	
>25-50 Insufficiency		Likely to be asymptomatic	Lifestyle advice* and Supplementation
>50 Adequate		Generally considered adequate for bone and overall health Remember levels may decrease over autumn/winter	Dietary/lifestyle advice*

* Lifestyle advice: Vitamin D and the Sun Consensus statement 2010, <u>http://www.bad.org.uk/for-the-public/skin-cancer/vitamin-d/vitamin-d-consensus-2010</u>

Note: Vitamin D status is determined on **total** 25-OH Vitamin D level (25-OH Vitamin D2 + 25-OH Vitamin D3) if 25-OH Vitamin D2 and 25 OH Vitamin D3 are reported separately.



<u>Vitamin D deficiency</u> <u>Predisposing factors for vitamin D deficient bone disease (rickets)</u>

- Occurs mainly in dark skinned infants and teenagers
- Lack of skin exposure to the sun
 - o Particularly with some types of traditional clothing
 - o During winter months
 - Spend very little time outdoors (e.g. those who are disabled)
- Use of sun block
- Prolonged breast feeding
- Exclusion diets
- Vegetarian / vegan diet
- Infants over 6 months who have not started to take a good range of solid foods
- Malabsorptive disease states
- Renal/liver disease
- Obesity (BMI > 98th BMI for age centile)
- Immobility
- Anticonvulsant treatment (e.g. sodium valproate, carbamazepine)
- Family history of vitamin D deficiency

Clinical presentation of vitamin D deficiency

- Vitamin D deficiency is usually asymptomatic but infants and young children may present with classic features of bow legs, swollen wrists and muscular weakness e.g. delayed walking. Severe cases may have bone pain presenting as unexplained crying.
- When present, symptoms are often vague and in teenagers may present as aches and pains in legs. Positive Gower's sign is an early clue (proximal myopathy).
- Occasionally hypocalcaemia in (breastfeeding) infants may cause convulsions.
- Other symptoms or conditions associated with vitamin D deficiency include:
 - Rachitic rosary (swelling of the costochondral junctions)
 - o Craniotabes (skull softening with frontal bossing and delayed fontanelle closure)
 - o Delayed tooth eruption and enamel hypoplasia
 - Cardiomyopathy (in infants)
- The presence of low vitamin D levels in isolation does not necessarily indicate this to be the cause of symptoms, as deficiency is commonly found in young children and may only require supplementation.

Investigations (when symptomatic vitamin D deficiency clinically suspected)

Clinicians should have a low index of suspicion for rickets, but routine supplementation is of more value than investigating large numbers of children without overt symptoms.

Investigation may be of help if adherence is expected to be poor or symptoms develop.



Symptomatic rickets should be investigated as below.

- Bone profile (Ca, Mg, phosphate, alkaline phosphatase)
- U&E
- FBC
- 25-OH Vitamin D levels (combined vitamin D2 and D3)

Additional tests depending on clinical context

- Ferritin (as asymptomatic iron deficiency often co-exists)
- 1,25 OH Vitamin D (if suspecting **renal** rickets or where vitamin D levels are normal but biochemistry indicates vitamin D bone disease). This investigation should not be done routinely and should only be requested by specialists.
- Parathyroid hormone (not routinely done unless biochemistry is atypical for nutritional vitamin D deficiency, or clinical rickets)
- X-ray knee or wrist (only if the patient clinically has rickets or significant symptoms)

Table 2: Differential diagnosis						
	Calcium	Phosphate	Alkaline	Parathyroid	Total 25-OH-	1,25 Vit D
			Phosphatase	hormone	Vitamin D	(not done
			(AlkP)	(PTH)	2+3	routinely)
Nutritional vitamin D deficiency						
Dietary lack and malabsorption	low or	low or	high or normal	high or	low	
	normal	normal		normal		
Renal rickets	Low	high	high	high	normal	verylow
Inherited vitamin D deficiency	Inherited vitamin D deficiency					
Vit D dependent rickets	Low	low	high	high	normal	low
(Pseudo-vitamin D deficiency)						
Hereditary vitamin D	Low	low	high	high	normal	very high
resistance (receptor mutation)						
Hypophosphataemic rickets						
Hypophosphataemic rickets	Normal	low	high	Normal (can	normal*	variable
				be low/high)		
					*ina	ppropriately so

Therapeutic treatment of vitamin D deficiency (< 25 nmol/L)

In patients over 6 months of age, **aim for a TOTAL replacement dose of 250,000 units. This can be given as daily or weekly replacement doses as below;** the prescribed administration schedule should aim to maximise treatment adherence.

Table 3:

Age	Less than	1 month –	Over 6 months – 12 years	Over 12 – 18 years
	1 month	6 months		
Dose of colecalciferol or ergocalciferol	1000 units daily (for 4-6 weeks initially then re-check level)	3000 units daily (for 12 weeks)	6000 units daily (for 6 weeks)	10,000 units daily (for 4 weeks)

Ref: 3,4,5



*The following regimen may promote adherence:-

Capsules: colecalciferol 20,000 units **daily for one week (7 days),** then 20,000 units **weekly for 5 weeks** (i.e. total of 12 doses of 20,000 units)

Liquid: 25,000 units *daily for one week (7 days)* then 25,000 units *weekly for 3 weeks* (i.e. total of 10 doses of 25,000 units)

(The guidance from the National Osteoporosis Society⁽⁶⁾ suggests a total replacement dose of 300,000 units. Clinical experience at Alder Hey has shown that a total replacement dose of 250,000 units is sufficient to bring the Vitamin D level up adequately.)

Consider whether a licensed formulation can be used (some small flexibility in the prescribed dose may enable this). Alternatively the off-label use of a licensed formulation or the use of an unlicensed formulation may be necessary.

Once the maximum total dose of 250,000units has been reached the initial therapeutic treatment with vitamin D should be reduced to supplemental doses due to the significant risk of hypercalcaemia.³

There is little evidence to support the need for calcium supplementation, but calcium intake from food should be assessed and improved if needed. If this is not achievable then consider calcium supplementation.

NB. Vitamin D 200 units = 5 micrograms of colecalciferol (D3) = 5 micrograms of ergocalciferol (D2).

Monitoring treatment response

• Review at the end of the treatment course. Ask the patient to bring all of their vitamin D medicine bottles to the review, to assess adherence. Consider repeating a blood test if symptoms persist and there is evidence of non-compliance.

If results are abnormal (vitamin D levels are deficient)

- Check compliance with therapy
- Continue treatment for a further 1 month *and*
- Check, bone profile (+/-PTH) and
- Continue until biochemistry normal, unless symptoms persist. In which case refer to a specialist.

NICE Clinical Knowledge Summaries follow up recommendations:

- At the end of treatment with high dose vitamin D:
 - Check bone profile (calcium, phosphate, ALP, magnesium). Consider checking calcium levels more regularly (e.g. every 1-2 weeks in the first months of treatment) in children and young people receiving calcium supplements in addition to high dose vitamin D
 - If hypercalcaemia identified, assess the person's state of hydration, and consider admission if the person is dehydrated. Discontinue calcium supplement immediately
 - If calcium levels are normal, do not recommend long-term calcium supplements. If the person is taking a calcium supplement, advise that it should be stopped
 - If hypocalcaemia is identified and the person is symptomatic (irritability, tetany, seizures or other neurological abnormalities), treat accordingly



- After 3–6 months of treatment with high dose vitamin D, check serum 25-hydroxyvitamin D (25[OH]D) levels
- Please note that 25-OH Vitamin D2 (Ergocalciferol) levels may be underestimated by some Vitamin D methods of analysis. If the patient is receiving Vitamin D2 supplements then measurement of Vitamin D using Mass Spectrometry is recommended (separate 25-OH Vitamin D2 and 25-OH Vitamin D3 reported). For further information contact the Duty Biochemist (0151 252 5486 or Ext 2486 or <u>duty.biochemist@alderhey.nhs.uk</u>).
 - If 25(OH)D levels are greater than 50nmol/L and bone profile is normal:
 - Advise that the person should take a daily vitamin D supplement throughout the year
 - If 25(OH)D levels are below 50nmol/L, consider other possible causes, including poor compliance with treatment or an underlying disease (e.g. renal or liver disease or malabsorption
 - If symptoms and signs have not improved despite satisfactory 25(OH)D levels, consider an alternative diagnosis and refer to a specialist for advice

When to refer to the Metabolic Bone Service (MBS) at Alder Hey

- Patients who show a poor response to treatment
- Patients with symptomatic rickets with significant metabolic abnormalities, e.g. persistently low phosphate
- Where a secondary cause is suspected, e.g. liver, malabsorption or renal disease
- Metabolic bone disease, not related to vitamin D deficiency

Poor adherence to treatment

If poor adherence to treatment is a contributory cause, the metabolic bone service would consider giving high dose bolus ergocalciferol therapy (called Stoss 'bolus' therapy) which can be given orally or by IM injection.

Ergocalciferol injection 300,000units/mL is a licensed preparation and for this reason it is the preparation of choice. In circumstances where this injection is unavailable then colecalciferol injection 300,000units/mL can be used as an alternative. The colcecalciferol injection is unlicensed in the UK. The pharmacy department can advise on available stock.

In the event that patients do not demonstrate an appropriate response to Stoss therapy with either product, they should be referred to the Metabolic Bone Team for further investigation.

Stoss therapy

- Oral ergocalciferol 150,000 units (3 x 50,000 unit capsules) as an observed dose every 3 months until biochemistry returns to normal.
- An alternative regimen of 50,000 units orally once a month for 3 months can be used.



- Ergocalciferol injection (available as 300,000 unit/ml) can be given by intra-muscular injection at a dose of 150,000 units (prepare to repeat after 1 month) or at a dose of 300,000 units (which may last for 3 months).
- Daily supplementation with vitamin D should be continued.
- Calcium supplementation is often given concurrently in infants when hypocalcaemia exists.

Parents must be informed of the symptoms of hypercalcaemia when starting high dose vitamin D (Stoss) therapy (e.g. anorexia, nausea, vomiting, headache, abdominal pain, polyuria) and advised to seek medical attention if their child develops any of these symptoms. Whenever Stoss therapy is given the bone profile must be checked after 1 month to ensure that hypercalcaemia has not occurred.

Education on longer term vitamin D health

- To prevent recurrence in patients who have completed treatment with therapeutic doses, long term supplementation and safe sun exposure are advised.
- Explain that it can take between 1-2 years for the bones to remodel.
- Explain that body stores take a long time to be replenished and so supplements are needed for a long time.
- Advise that siblings and other family members should also be supplemented.

Vitamin D and Covid-19 Infection

There is little evidence for using Vitamin D supplements to prevent or treat Covid-19.

Vitamin D supplements should NOT be offered to adults or children solely to prevent or treat Covid-19 except as part of a clinical trial.

However children and adults should be encouraged to follow UK government advice on taking a Vitamin D supplement to maintain bone and muscle health - see above.

VITAMIN D PREPARATIONS (stocked at Alder Hey)

Vitamin D alone (for therapeutic treatment)

- Colecalciferol (Fultium D3[™]) 3,200 unit capsule [licensed product]
- Colecalciferol 20,000 unit capsules (Fultium™ D3 capsules). [Licensed product]
- Ergocalciferol (or colecalciferol) capsules 1.25 mg (50,000 units) only for use under supervision at Alder Hey (referrals to Metabolic Bone Service MBS) [Licensed product]
- Colecalciferol (InVita D3[™]) oral solution 25,000 unit/ml; 1 ml ampoule for oral use [Licensed product]
- Colecalciferol (Thorens® Vitamin D3) oral solution 10,000 unit/ml [licensed product] 10 ml bottle
- Ergocalciferol injection 300,000 units/ml (through MBS) [Licensed product]
- Colecalciferol injection 300,000units/ml [unlicensed product]



Multivitamin preparations (available for supplementation)

To ensure adequate vitamin D status in healthy children and well children with vitamin D insufficiency, and to prevent recurrence of deficiency after vitamin D treatment.

• Healthy Start Children's Vitamin Drops (community clinics only) - 5 drops daily contains 7.5 micrograms (300 units) vitamin D₃, 233 micrograms vitamin A and 20 mg vitamin C.

Children can get these supplements free without prescription from 1 month to 4 years if parents are in receipt of welfare benefits.

In Liverpool, Healthy Start Vitamins are free for all children up to 2 years of age from the Children's Centres.

The product is suitable for vegetarians and free from milk, egg, gluten, soya and peanut residues.

http://www.healthystart.nhs.uk

Abidec[™] or Dalavit[™] 0.6 ml daily provides 400 units vitamin D daily. (Available on prescription or to buy). [Licensed products]
 NB. Abidec[™] contains arachis oil – avoid using in patients with peanut allergy.

Multivitamin preparations containing vitamin A are not suitable for patients with chronic renal failure. These patients should receive vitamin D supplementation alone.

Vitamin D preparations (available for supplementation)

- Colecalciferol (Fultium D3[™]) 800 unit capsule [Licensed product]
- Colecalciferol (Invita D3) 400 unit soft capsule [Licensed product]

References

1. Chief Medical Officers (UK). Vitamin D - advice on supplements for at risk groups 2012 CEM/CMO/2012/04 Gateway reference 17193.

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213703/dh_132508.pdf

- 2. Moy R.J et al Successful public health action to reduce the incidence of symptomatic vitamin D deficiency. Archives of disease in childhood 2012;97:952-954
- 3. <u>NICE Clinical Knowledge Summary Vitamin D deficiency in children (Nov 2016)</u>
- 4. Royal College of Paediatrics and Child Health Guide for vitamin D in childhood (Oct 2013)
- 5. British National Formulary for Children Colecalciferol <u>https://bnfc.nice.org.uk/drug/colecalciferol.html accessed</u> <u>3/7/20 and ergocalciferol accessed 3/7/20</u> https://bnfc.nice.org.uk/drug/ergocalciferol.html
- 6. National Osteoporosis Society. Vitamin D and Bone Health: A Practical Clinical Guideline for Management in Children and Young People 2015.
- 7. COVID-19 rapid guideline: Vitamin D. NICE guideline NG187 Published 17 December 2020.
- 8. www.nice.org.uk/guidamce/ng187



Other relevant guidance

Guide for Vitamin D in childhood. RCPCH October 2013 http://www.rcpch.ac.uk/system/files/protected/page/vitdguidancedraftspreads%20FINAL%20for%20website.pdf

East and South East England Specialist Pharmacy services. Vitamin D deficiency and insufficiency: Using appropriate available products January 2013

<u>http://www.medicinesresources.nhs.uk/upload/documents/Communities/SPS_E_SE_England/Vitamin_D_product_a</u> vailability_Jan_2013_V1_FINAL.pdf

Alder Hey Children's NHS Foundation Trust

Vitamin D Deficiency and Nutritional Rickets:			
Supplementation and Treatment in Infants and Children			
Version:	7		
Ratified by:	Medicines Management and Optimisation Committee (MMOC)		
Date ratified:	23 rd February 2021cbCA		
Name of originator/author:	Alder Hey Children's NHS FT - Vitamin D Guideline Working Group		
	Anita Aindow (Pharmacy Medicines Information)*		
	Catrin Barker (Chief Pharmacist)*		
	Dr James Bunn (General Paediatrics) [2015 guidelines]		
	Catherine Collingwood (Biochemisty)*		
	Dr Poonam Dharmaraj (Endocrinology)*		
	Andrea Gill (Pharmacy) [2015 guidelines]		
	Dr Renuka Ramakrishnan (Endocrinology)*		
	Ruth Watling (Dietetics)*		
	Emma Whittle (Dietetics)*		
	See Mun Wong [2018 guidelines]		
	*2015 and 2018 guidelines		
Name of responsible committee:	Medicines Management and Optimisation Committee (MMOC)		
Name of executive sponsor:	N/A		
Key search words:	Vitamin D, Nutritional Rickets, Guidelines, COVID-19		
Date issued:	13 th April 2021		
Review date:	February 2024		

Version Control Table					
Version	Date	Author(s)	Status	Comment(s)	
7	Feb 21	Anita Aindow,	Current		
		Catrin Barker			
6	Jul 20	Anita Aindow,	Archived		
		Catrin Barker,			
		Poonam Dharmaraj,			
		Renuka Ramakrishnan			
5	Sep 18	Anita Aindow,	Archived		
		See Mun Wong,			
		Poonam Dharmaraj,			
		Renuka Ramakrishnan			
4	Nov 15	Anita Aindow,	Archived		
		See Mum Wong (Formulary			
		Pharmacist)			
3	Apr 15	Anita Aindow	Archived		
		(Senior Medicines			
		Information Pharmacist)			
2	Dec 14	Catherine Collingwood	Archived		
		(Principal Biochemist)			
1	Sep 14	Alder Hey Children's NHS	Archived		
		Foundation Trust Vitamin D			
		Guideline Working Group			



Review and Revision(s) Log					
	Re	Ince version 1			
Section Number	Page Number	Revision(s) made	Reason for revision(s)		
Background	1, 7, 8	Added UK Gov recommendations	To remind users about the standard		
	7	Added info on Vit D and COVID-19 Infection	doses of Vit D for supplementation and to reflect NICE guidance around Vit D		
References	8	Updated NICE reference and deleted info on Vit D and COVID-19 Infection	and COVID		
	8	Added information about Vitamin D and COVID 19 infection plus reference to NICE rapid evidence summary	New Information published		
		 Reviewed and updated: Added standard prevention doses (table 1). Higher doses up to 1000units daily may be used at the discretion of the clinician. Extended list of pre-disposing factors Extended symptoms or conditions associated with vitamin D deficiency Amended durations of treatment for daily doses and amended total replacement dose to 250,000units (NB we are aware other guidance suggests a total replacement dose of 300,000units. Clinical experience at Alder Hey has shown 250,000units to be sufficient) Included NICE CKS follow up recommendations 	In line with current practice		
	6	Colecalciterol (Thorens® Vitamin D3) oral solution included - removed Colecalciferol oral solution 3000unit/ml	Licensed product now available - updated		
Colecalciferol 20,000 unit capsules	6	Biovitamin [™] replaced by Fultium D3 capsules (licensed product) Also available in primary care removed	Licensed product now available to use instead of unlicensed		
			Updated to reflect laboratory advise on determination of Vitamin D status		